Main characteristics of the 242 patients with noninfectious mixed CryoVas included in the survey, according to the type of MC
Characteristics . | All patients (n = 242) . | Type II CryoVas (n = 203) . | Type III CryoVas (n = 27) . | P . |
---|---|---|---|---|
Epidemiologic features | ||||
Age at diagnosis, y, mean ± SD | 62.6 ± 14.5 | 63.2 ± 14.5 | 60.4 ± 14.9 | .36 |
Female sex, n (%) | 163 (69) | 136 (69) | 20 (74) | .66 |
Causes, n (%) | .36 | |||
Essential MC | 117 (48) | 95 (47) | 15 (56) | |
Connective tissue disease | 73 (30) | 61 (30) | 9 (33) | |
Hematologic disease | 52 (22) | 47 (23) | 3 (11) | |
Clinical manifestations, n (%) | ||||
Skin | 201 (83) | 172 (85) | 19 (70) | .10 |
Purpura | 182 (75) | 158 (78) | 15 (56) | .02 |
Acrocyanosis | 64 (26) | 52 (26) | 9 (33) | .49 |
Ulcers | 39 (16) | 32 (16) | 6 (22) | .41 |
Necrosis | 35 (14) | 28 (14) | 5 (19) | .56 |
Peripheral nerve | 125 (52) | 114 (56) | 6 (22) | .001 |
Sensory | 50 (21) | 46 (23) | 1 (3) | .02 |
Sensorimotor | 75 (31) | 68 (33) | 5 (19) | .13 |
Joints | 97 (40) | 84 (41) | 8 (30) | .30 |
Arthralgias | 72 (30) | 61 (30) | 7 (27) | .82 |
Arthritis | 25 (10) | 23 (11) | 1 (3) | .32 |
Kidney | 84 (35) | 77 (38) | 4 (15) | .02 |
Gastrointestinal tract | 13 (5) | 12 (6) | 0 (0) | .37 |
CNS | 5 (2) | 3 (1) | 2 (7) | .11 |
Pulmonary | 5 (2) | 4 (2) | 1 (3) | .47 |
Biologic features | ||||
Cryoglobulin level, g/L, mean ± SD | 0.94 ± 1.61 | 1.01 ± 1.69 | 0.42 ± 0.54 | .05 |
C3 level, g/L (0.80-1.40), mean ± SD | 0.86 ± 0.31 | 0.83 ± 0.31 | 1.07 ± 0.33 | .009 |
C4 level, g/L (0.14-0.40), mean ± SD | 0.07 ± 0.09 | 0.06 ± 0.07 | 0.16 ± 0.11 | < .0001 |
Creatinine level, μmol/L (55-105), mean ± SD | 113 ± 90 | 112 ± 77 | 115 ± 136 | .86 |
GFR, mL/min, mean ± SD* | 69 ± 31 | 67 ± 30 | 78 ± 31 | .03 |
GFR < 60 mL/min, n (%)* | 93 (38) | 86 (42) | 5 (19) | .02 |
Outcome | ||||
Follow-up, mo, mean ± SD | 51 ± 54 | 52 ± 52 | 40 ± 46 | .28 |
Serious infections, n (%) | 54 (22) | 51 (25) | 2 (7) | .05 |
Death, n (%) | 42 (17) | 40 (20) | 1 (4) | .06 |
Characteristics . | All patients (n = 242) . | Type II CryoVas (n = 203) . | Type III CryoVas (n = 27) . | P . |
---|---|---|---|---|
Epidemiologic features | ||||
Age at diagnosis, y, mean ± SD | 62.6 ± 14.5 | 63.2 ± 14.5 | 60.4 ± 14.9 | .36 |
Female sex, n (%) | 163 (69) | 136 (69) | 20 (74) | .66 |
Causes, n (%) | .36 | |||
Essential MC | 117 (48) | 95 (47) | 15 (56) | |
Connective tissue disease | 73 (30) | 61 (30) | 9 (33) | |
Hematologic disease | 52 (22) | 47 (23) | 3 (11) | |
Clinical manifestations, n (%) | ||||
Skin | 201 (83) | 172 (85) | 19 (70) | .10 |
Purpura | 182 (75) | 158 (78) | 15 (56) | .02 |
Acrocyanosis | 64 (26) | 52 (26) | 9 (33) | .49 |
Ulcers | 39 (16) | 32 (16) | 6 (22) | .41 |
Necrosis | 35 (14) | 28 (14) | 5 (19) | .56 |
Peripheral nerve | 125 (52) | 114 (56) | 6 (22) | .001 |
Sensory | 50 (21) | 46 (23) | 1 (3) | .02 |
Sensorimotor | 75 (31) | 68 (33) | 5 (19) | .13 |
Joints | 97 (40) | 84 (41) | 8 (30) | .30 |
Arthralgias | 72 (30) | 61 (30) | 7 (27) | .82 |
Arthritis | 25 (10) | 23 (11) | 1 (3) | .32 |
Kidney | 84 (35) | 77 (38) | 4 (15) | .02 |
Gastrointestinal tract | 13 (5) | 12 (6) | 0 (0) | .37 |
CNS | 5 (2) | 3 (1) | 2 (7) | .11 |
Pulmonary | 5 (2) | 4 (2) | 1 (3) | .47 |
Biologic features | ||||
Cryoglobulin level, g/L, mean ± SD | 0.94 ± 1.61 | 1.01 ± 1.69 | 0.42 ± 0.54 | .05 |
C3 level, g/L (0.80-1.40), mean ± SD | 0.86 ± 0.31 | 0.83 ± 0.31 | 1.07 ± 0.33 | .009 |
C4 level, g/L (0.14-0.40), mean ± SD | 0.07 ± 0.09 | 0.06 ± 0.07 | 0.16 ± 0.11 | < .0001 |
Creatinine level, μmol/L (55-105), mean ± SD | 113 ± 90 | 112 ± 77 | 115 ± 136 | .86 |
GFR, mL/min, mean ± SD* | 69 ± 31 | 67 ± 30 | 78 ± 31 | .03 |
GFR < 60 mL/min, n (%)* | 93 (38) | 86 (42) | 5 (19) | .02 |
Outcome | ||||
Follow-up, mo, mean ± SD | 51 ± 54 | 52 ± 52 | 40 ± 46 | .28 |
Serious infections, n (%) | 54 (22) | 51 (25) | 2 (7) | .05 |
Death, n (%) | 42 (17) | 40 (20) | 1 (4) | .06 |
For 12 patients, cryoglobulinemia was not typed. Normal values are indicated for C3, C4, and creatinine levels between parentheses. Type II is MC with a monoclonal component. Type III is MC with only polyclonal immunoglobulins.
GFR was assessed with the Modified Diet in Renal Disease equation.